<DOC>
	<DOCNO>NCT01373411</DOCNO>
	<brief_summary>Subjects consent study prior Coronary Artery Bypass Graft ( CABG ) randomly assign receive either ticagrelor 90 mg bid placebo bid start within 48 hour surgery . Subjects remain study drug minimum 12 month time receive telephone follow-up one nine month follow CABG clinic visit three , six , twelve month follow CABG .</brief_summary>
	<brief_title>Ticagrelor Aspirin Prevention Cardiovascular Events After Coronary Artery Bypass Surgery</brief_title>
	<detailed_description>Patients screen eligibility pre-CABG , informed consent sign randomization . Aspirin 81mg/d start within 12 hour CABG per routine practice . Study medication start within 48 hour CABG contraindication . Patients randomize ticagrelor 90mg bid ( load dose ) placebo bid 1 year follow CABG . Aspirin 81mg/d continue least 1 year post-CABG . Other cardiac medication discretion treat physician per standard practice . Patients follow daily hospital stay . Outpatient visit schedule 3 , 6 12 month . There also telephone contact 1 9 month . CT Substudy : Patients CT angiography substudy ( first 240 enrolled subject ) cardiac CT angiogram evaluate bypass graft patency 3-month follow-up.Grafts separately evaluate base upon conduit use , internal mammary , radial , saphenous vein graft . Graft patency define contrast filling conduit coronary artery beyond anastomosis . Grafts ≥50 % stenosis also record . The location stenosis also record ( proximal anastomosis , body graft , distal anastomosis ) . CT angiograms evaluate 2 interpreter ( radiologist cardiologist ) blind randomize treatment , review 3rd interpreter disagreement . If consensus could reach among 3 interpreter , graft deem analyzable , subject invasive coronary angiography definitive assessment clinically indicate . The primary efficacy endpoint composite all-cause mortality , MI , stroke , repeat revascularization within 1 year follow CABG . Secondary endpoint include individual endpoint all-cause mortality , cardiovascular death , MI , stroke , repeat revascularization .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Males females ≥ 19 year ≤ 80 year old undergoing isolate CABG 2 . Females childbearing age must negative pregnancy test enrollment 1 . Patients undergo combined valve aortic surgery 2 . Patients require oral anticoagulant therapy discharge stop ( e.g . atrial fibrillation CHADS2 score ≥ 2 , pulmonary embolism , deep venous thrombosis ) 3 . Known allergy intolerance aspirin , clopidogrel ticagrelor 4 . Patients active bleed history bleed diathesis 5 . Patients previous intracranial hemorrhage time , ischemic stroke within 14 day 6 . Patients severe liver disease ( e.g . ascites sign coagulopathy ) 7 . Patients preoperative persistent postoperative Type 2 seconddegree AV block , 3rd degree AV block , without permanent pacemaker 8 . Patients endstage renal failure require dialysis 9 . For patient enrolled CT angiography substudy , renal dysfunction eGFR &lt; 50 ml/min exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>CABG</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Coronary Artery Bypass Surgery</keyword>
</DOC>